Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Neurol. 2014 Mar;13(3):287-305. doi: 10.1016/S1474-4422(13)70294-1. Epub 2014 Feb 17.

Mood and behavioural effects of subthalamic stimulation in Parkinson's disease.

Author information

1
Movement Disorder Unit, Department of Psychiatry and Neurology, Centre Hospitalier Universitaire de Grenoble, Joseph Fourier University, Grenoble, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 836, Grenoble Institut des Neurosciences, Grenoble, France; Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy.
2
Movement Disorder Unit, Department of Psychiatry and Neurology, Centre Hospitalier Universitaire de Grenoble, Joseph Fourier University, Grenoble, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 836, Grenoble Institut des Neurosciences, Grenoble, France.
3
Movement Disorder Unit, Department of Psychiatry and Neurology, Centre Hospitalier Universitaire de Grenoble, Joseph Fourier University, Grenoble, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 836, Grenoble Institut des Neurosciences, Grenoble, France. Electronic address: Paul.Krack@ujf-grenoble.fr.

Abstract

Deep-brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for motor complications in Parkinson's disease. 20 years of experience with this procedure have contributed to improved understanding of the role of the STN in motor, cognitive, and emotional control. In Parkinson's disease, the pathological STN neuronal activity leads to motor, cognitive, and emotional inhibition. Deafferentation of the STN by DBS can reverse such behavioural inhibition. The release of this brake allows both motor and non-motor improvement, but can also be associated with excessive motor, cognitive, and emotional behavioural disinhibition. Conversely, the notable reduction in anti-parkinsonian drug dose allowed by motor improvement can unveil mesolimbic hypodopaminergic behaviours such as apathy, anxiety, or depression. Fine-tuning of stimulation parameters with dopaminergic drugs is necessary to prevent or improve pathological behaviours.

PMID:
24556007
DOI:
10.1016/S1474-4422(13)70294-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center